918346-06-2

Upstream product

• 1194-65-6 2,6-dichloro-benzonitrile 
• 1033586-53-6 N-(4-bromo-2-chlorophenyl)-2,6-dichlorobenzamidine 
• 918350-19-3 1-(4-bromo-2-chlorophenyl)-2-(2,6-dichlorophenyl)-1H-imidazole-4-carboxylic acid ethyl ester 
• 373384-18-0 3-(methanesulfonyl)phenylboronic acid 

Downstream Products

• 1033586-98-9 C₂₃H₁₄Cl₄N₂O₃S 
• 1033586-55-8 1-(3-chloro-3'-methanesulfonylbiphenyl-4-yl)-2-(2,6-dichlorophenyl)-1H-imidazole-4-carboxylic acid 
• 1033575-79-9 2-[1-(3-chloro-3'-methanesulfonyl-biphenyl-4-yl)-2-(2,6-dichlorophenyl)-1H-imidazol-4-yl]-4,5-dihydrooxazole 
• 1033575-89-1 5-[1-(3-chloro-3'-methanesulfonylbiphenyl-4-yl)-2-(2,6-dichlorophenyl)-1H-imidazol-4-yl]-3-methyl[1,2,4]oxadiazole 
• 918349-06-1 1-(3-chloro-3'-methanesulfonylbiphenyl-4-yl)-2-(2,6-dichlorophenyl)-1H-imidazole-4-carboxylic acid (2-hydroxyethyl)amide 

Relevant academic research and scientific papers

LXR AND FXR MODULATORS

Compounds of the invention are disclosed, such as compounds of formulae LX - LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.